Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Yipai Sunshine (02522.HK), indicating a slight reduction in holdings on October 27, 2025, with a decrease of 58,000 shares, representing a change of -0.05% [1][2] - Over the past five trading days, southbound funds have increased their holdings for four days, resulting in a total net increase of 1.4635 million shares [1][2] - In the last twenty trading days, there were nine days of net increases in holdings by southbound funds, totaling 245,000 shares [1][2] Group 2 - As of now, southbound funds hold 128 million shares of Yipai Sunshine, which accounts for 43.56% of the company's total issued ordinary shares [1][2] - Yipai Sunshine Group Co., Ltd. primarily engages in specialized medical imaging services in China, providing imaging services and solutions [2] - The company operates three segments: imaging center services, imaging solutions, and Yipai Cloud services, supporting the development of imaging center services and data-driven operations [2]

Core Insights - Midea Group's medical segment, through its subsidiary Wandong Medical, has initiated a strategic cooperation with the Chinese Academy of Sciences' Electrical Engineering Research Institute to focus on high-field, helium-free magnetic resonance technology [1][2] - The collaboration aims to achieve a "1+1>2" effect by integrating industry needs with scientific innovation, contributing to the advancement of high-end medical equipment in China [1] - Wandong Medical is recognized as a leading enterprise in medical imaging in China, with a comprehensive industrialization system and advanced independent technology matrix [2] Company Overview - Wandong Medical has established a mature industrialization system covering core areas such as system design integration, software development, spectrometer manufacturing, and sequence reconstruction [2] - The company has extensive experience in managing national-level research and demonstration projects and has undertaken multiple national projects, including the "AI+Health" initiative [2] - Wandong Medical's products have been included in Beijing's major technology equipment directory and have received "three new" certifications, showcasing its full-chain capabilities in magnetic resonance system research, manufacturing, and industrialization [2] Strategic Goals - The partnership will focus on joint efforts in high-field, helium-free magnetic resonance technology, aiming to efficiently translate laboratory results into clinical products [2] - The collaboration seeks to establish a synergistic system encompassing "technology research and development—result transformation—clinical application—industry promotion" [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 影禾醫脈發佈全球首個基座大模型驅動的AI輔助診斷產品 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，2025年10月16日，由本集團參股孵化的人工智能公司上海影 禾醫脈智能科技有限公司（「影禾醫脈」），正式發佈全球首個基於醫學影像基座大 模型「影禾覓芽®」研發的AIR（路徑級AI輔助診斷產品）——胸部CT平掃輔助診斷 AIR（「AIR產品」）。AIR產品標誌着醫學影像AI正式從「單病種小模型」的1.0時 代，邁入「基座大模型驅動」的2.0時代，具備全病灶、全病種、多器官協同診斷 能力，是醫學影像智能診斷領域的一項里程碑式突破。 AIR產品不僅 ...

Core Insights - The article highlights the launch of iMedImage™, a large-scale medical imaging model developed by Deshi Bio, which is based on 80 million data points and supports 19 modalities, covering over 90% of clinical scenarios [1] - iMedImage™ significantly reduces data dependency and development costs by over 90%, requiring only hundreds of images and a few days for training specialized models compared to traditional methods [1] - Deshi Bio has received the Sullivan Global Medical Imaging Foundation's Innovation Award for iMedImage™ and aims to lower the barriers for AI applications in medical research and clinical settings [1] - During the event, Deshi Bio signed strategic cooperation agreements with Wutongshu, Inspur Group, and ZTE Corporation to advance the research and industrial application of AI in medical imaging [1] Summary by Categories Product Development - iMedImage™ is the largest general medical imaging model globally, trained on 80 million data points [1] - The model supports 19 imaging modalities, including chromosome, CT, and MRI, and covers over 90% of clinical scenarios [1] - The training process is automated and requires minimal data input, significantly reducing the time and resources needed for model development [1] Cost Efficiency - iMedImage™ reduces the data dependency for specialized models to just hundreds of images and training time to a few days [1] - Development costs are decreased by over 90% compared to traditional specialized models [1] Industry Recognition and Collaboration - The model has won the Sullivan Global Medical Imaging Foundation's Innovation Award, indicating its significance in the field [1] - Deshi Bio has established strategic partnerships with Wutongshu, Inspur Group, and ZTE Corporation to promote the application of AI in medical imaging [1]

Core Viewpoint - The stock of Yimai Sunshine (02522) experienced a significant increase of over 10%, reaching a price of 17.17 HKD, with a trading volume of 323 million HKD, following the announcement of a new AI product in collaboration with Alibaba Cloud [1] Group 1: Product Launch - Yimai Sunshine's AI company, Yinghe Yimai, launched the "Medical Imaging Large Model Intelligent Computing Machine MIIA-X1" during the 2025 Alibaba Cloud Summit [1] - MIIA-X1 integrates the "Yinghe Mijia" base model as its intelligent core, utilizing Alibaba Cloud AI Stack hardware, and combines Yimai Sunshine's imaging data resources with clinical scenarios [1] - The product aims to empower hospitals to quickly build localized AI capabilities, supporting research data governance, model fine-tuning, and clinical tool development [1] Group 2: Data Transaction - Yimai Sunshine announced the completion of its first data transaction on September 1, with CT chest lesion annotation data listed on the Shanghai Data Exchange on August 25 [1] - The transaction was conducted in collaboration with a data technology company and Beijing International Big Data Exchange, showcasing the company's ability to monetize its core data assets [1] - This partnership highlights the company's expertise and market value in the field of medical imaging data [1]

Core Viewpoint - The stock price of Yimai Sunshine (02522) increased by over 10% after the announcement of the launch of the "Medical Imaging Large Model Intelligent Computing Machine MIIA-X1" in collaboration with Alibaba Cloud during the 2025 Alibaba Cloud Conference [1] Company Developments - Yimai Sunshine's stock rose by 9.85% to HKD 17.17, with a trading volume of HKD 323 million [1] - The MIIA-X1 integrates the "Yinghe Mijia" base model as its intelligent core, utilizing Alibaba Cloud AI Stack hardware, and combines Yimai Sunshine's imaging data resources with clinical scenarios [1] - The company aims to empower hospitals to quickly build localized AI capabilities, supporting research data governance, model fine-tuning, and clinical tool development [1] Data Transaction - Yimai Sunshine completed its first batch of data transactions on September 1, with CT chest lesion annotation data listed on the Shanghai Data Exchange on August 25 [1] - The company, through its subsidiary Beijing Yimai Information, signed a tripartite cooperation contract with a data technology company and Beijing International Big Data Exchange, successfully completing the transaction [1] - This collaboration provides a new model for monetizing the company's core data assets and highlights its professional capabilities and market value in the medical imaging data field [1]

Group 1: Company Strategy and Focus Areas - The company aims to enhance its core competitiveness through industrial investments, focusing on the medical imaging and non-destructive testing sectors [2][3] - The company is actively seeking acquisition opportunities that align with its strategic development [2][3] - The company plans to expand its product portfolio through both depth and breadth, targeting cross-sector development [2][3] Group 2: Product Development and Market Position - The company has developed a portable multi-modal medical imaging system for emergency rescue applications, integrating portable DR and ultrasound devices [3][4] - The company’s industrial ultrasonic testing equipment is widely used in aerospace, petrochemicals, energy, and transportation sectors [4][5] - Key products include multi-modal medical imaging systems, specialized ultrasound diagnostic equipment, and automated non-destructive testing devices, which are expected to drive future revenue growth [5][6] Group 3: Research and Development - The company has participated in multiple national and provincial major research projects, with details disclosed in its prospectus and periodic reports [4][5] - The company has made advancements in AI-based breast cancer screening technology, enhancing the accuracy and efficiency of early detection [5][6] Group 4: Marketing and Sales Strategy - In 2025, the company will adjust its marketing strategy, focusing on major cities like Guangzhou, Shenzhen, Shanghai, and Beijing to strengthen its domestic and overseas marketing efforts [7][8] - The company aims to enhance its marketing network by attracting high-quality domestic and international distributors and improving local customer service capabilities [7][8] Group 5: Revenue Contribution - The sales revenue from surgical robots and automated non-destructive testing equipment constitutes a significant portion of the company's overall revenue [8]

Technological Innovation - The healthcare industry highlights the development of "portable MRI" technology, enabling faster diagnosis of stroke [1] - The medical imaging field emphasizes overcoming technical challenges in stroke imaging distortion through portable MRI technology [1] - The research sector acknowledges the promotion of portable MRI stroke imaging technology to primary care levels [1] Research & Development - The scientific community recognizes the dedication of researchers who spend hundreds of days and nights overcoming failures [1] - The academic field emphasizes that true breakthroughs stem from perseverance during challenging times [1] - The global science community acknowledges Qiu Yueqi as the first Chinese researcher to receive the "Young Scientist Translational Award" at the International Society for Magnetic Resonance in Medicine [1] Impact & Vision - The medical technology sector aims to make advanced medical imaging accessible to more people [1] - The healthcare industry showcases the power of Chinese youth in scientific research [1]

Core Insights - The medical imaging field faces a significant contradiction between high demand for services and a shortage of qualified professionals, with only 1.43 radiologists per 100,000 people in China [1] - AI is identified as a key tool to address the challenges in medical imaging, particularly in enhancing diagnostic accuracy and efficiency [1][2] - The AI-driven medical imaging market in China is projected to reach a scale of 2.4 billion yuan by 2024, with an expected annual growth rate of 60.2% until 2030 [1] Group 1 - The demand for medical imaging services in China reaches hundreds of millions of instances annually, while the disparity in diagnostic interpretations among different doctors can be as high as 20% under heavy workloads [1] - The integration of AI in medical imaging is one of the fastest-growing sectors in AI healthcare development, aiming to alleviate the burden on radiologists and improve diagnostic consistency [1] - The company, 德适生物, is developing a generalized foundational model for medical imaging that supports basic diagnostic capabilities for thousands of diseases [1] Group 2 - The implementation of AI is expected to allow doctors more time to learn advanced medical knowledge and to train specialized AI imaging models for rare and emerging cases, ultimately leading to more precise and standardized medical care [2] - This advancement is anticipated to help bridge the gap in healthcare quality between urban and rural areas [2]

Core Viewpoint - Yimai Sunshine (02522) has successfully completed its first data transaction, enhancing its market value and professional capabilities in the medical imaging data sector [1] Group 1: Data Transaction - Yimai Sunshine's first batch of data transactions was completed on September 1, following the listing of its CT chest lesion annotation data on August 25 at the Shanghai Data Exchange [1] - The transaction was conducted in collaboration with a data technology company and Beijing International Big Data Exchange, showcasing the company's ability to monetize its core data assets [1] Group 2: Financial Developments - The company plans to place 35 million shares, aiming to raise approximately 562 million HKD [1] - About 40% of the raised funds will be allocated to the development of data and artificial intelligence, focusing on enhancing capabilities in medical imaging data mining, annotation, and cleaning [1] - 30% of the funds will be used for expanding the medical imaging center business and enabling solution services through self-investment or acquisitions, targeting both domestic and international markets, including Hong Kong and Singapore [1]